The most common adverse effects from methylnaltrexone were abdominal cramps and flatulence, with rates of 30% to 40% and 15% to 20%, respectively. [15] Opioid withdrawal was not reported.

The potential approval by the FDA of methylnaltrexone and alvimopan will prompt pharmacy and therapeutics committees to evaluate these agents for inclusion in health-system formularies and ...